U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06802757) titled 'Posaconazole Research in Immunotherapy and Systemic Management' on Jan. 16.
Brief Summary: Triple-negative breast cancer (TNBC) is as sociated with shorter overall survival than other breast cancer subtypes, despite the use of curative-intent anthracycline- and taxane-based systemic chemotherapy. Neoadjuvant therapy is now also recognized as the standard treatment for patients with high-risk TNBC. The Keynote-522 study demonstrated that the application of pembrolizumab has raised the pathological Complete Response (pCR) rate in TNBC to over 60%, but nearly 40% of patients still do not achieve pCR. How to further improve the pCR rate ...